Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
Status:
Completed
Trial end date:
2017-11-09
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the reduction in insulin dose from baseline at Week
24 while keeping the blood glucose levels controlled (maintaining HbA1c values) when
ipragliflozin is administered once daily for 24 weeks in patients with type 2 diabetes
mellitus receiving insulin therapy.